Boston Scientific Acquires Valencia Technologies to Enter Implantable Tibial Nerve Stimulation Market

January 12, 2026, Global Medical Device GiantBoston Scientific (NYSE: BSX)Announced Agreement to Acquire Medical Technology Company Focused on Bladder Dysfunction TreatmentValencia Technologies。

The core objective of this acquisition is Valencia's eCoin® Implantable Tibial Nerve Stimulation (ITNS) System. This marks another strategic enhancement by Boston Scientific in the urology and pelvic health sector, following its acquisition of Axonics in 2024, signaling its formal entry into the high-growth ITNS niche market.

# Technical Breakdown: How eCoin Breaks the Deadlock in OAB Treatment?

Urgency Urinary Incontinence (UUI) is one of the most distressing symptoms for patients with Overactive Bladder (OAB). Traditional stepwise therapy includes pharmacological treatment and behavioral interventions, but these are often associated with significant side effects or poor adherence.

The eCoin® system developed by Valencia Technologies offers a novel mechanism of physical intervention:

• Miniaturized Design: The eCoin is coin-sized and features a fully integrated design. Unlike traditional sacral neuromodulation (SNM) systems that require long leads connected to the spinal region, the eCoin is a leadless implant.

• Minimally Invasive Implantation Site: The implantation site of this device is highly unique—located atSubcutaneous tissue on the medial aspect of the ankle and footThe procedure requires only local anesthesia and can be performed in an office setting.

• Automated Regulation Mechanism: Following implantation, the device intermittently and automatically stimulates the tibial nerve according to a pre-programmed protocol. By modulating the central nervous system’s control over bladder signals via neuromodulation, it alleviates detrusor overactivity.

  
  

# Clinical Validation: 68% Response Rate and Real-World Performance

eCoin received U.S. FDA approval in 2022, primarily for patients with urgency urinary incontinence (UUI) who are refractory to or intolerant of conservative therapies. Its core approval data were derived from a pivotal clinical trial:

• Significance of Efficacy: The trial showed that,68%of patients achieved at least post-implantation50%reduced frequency of urinary incontinence.

• Long-term Adherence: Since the device operates automatically and does not require frequent manual charging by the patient (utilizing a primary battery design with a lifespan typically lasting several years), it addresses the pain point of traditional percutaneous tibial nerve stimulation (PTNS), which necessitates weekly clinic visits.

• Safety: As a form of peripheral neuromodulation, its risks are significantly lower than those of the more invasive sacral nerve implantation, with an extremely low incidence of surgical complications.

# M&A Details and Timeline

According to the information disclosed by Boston Scientific:

• Transaction Amount: The specific amount has not been disclosed (but in early 2025, Valencia completed a $35 million financing round, with its valuation already in a period of rapid growth).

• Financial Forecast: The transaction is expected to be completed onFirst Half of 2026Closing completed. Boston Scientific expects the impact of this transaction on its 2026 adjusted earnings per share (EPS) to be negligible, although it will be somewhat dilutive under GAAP.

# Strategic Landscape: Boston Scientific“Dual-Wheel Drive” Logic

Meghan Scanlon, Senior Vice President of Urology at Boston Scientific, pointed out that ITNS is a “high-growth adjacent sector” within the urology business. Industry analysts believe that the acquisition of Valencia Technologies is not merely an expansion in scale, but rather a strategic move to build a comprehensive neuromodulation portfolio encompassing both sacral nerve modulation (SNM) and tibial nerve stimulation (ITNS).

1. Differentiated Coverage: Complementarity Between SNM and ITNS

Following the acquisition of Axonics in 2024, Boston Scientific has established a firm foothold in the sacral neuromodulation (SNM) market, where it directly competes with Medtronic’s InterStim. However, SNM procedures are relatively complex, requiring the implantation of sacral nerve leads.

• Advantages of ITNSlies in its "disposable-like" characteristics. The outpatient surgical procedure for implanting the eCoin in the ankle is significantly less complex than that for SNM.

• Tiered Diagnosis and Treatment Layout: Boston Scientific successfully captured patients who were “unwilling to undergo surgery in the spinal region” or who sought “simpler solutions during the office-based stage” through eCoin, achieving full lifecycle coverage of OAB treatment.

2. Synergy with Axonics and Existing Channels

Boston Scientific boasts a robust distribution network in urology. Valencia’s eCoin can be directly integrated into Boston Scientific’s established Pelvic Health sales channel, leveraging its existing urologist resources to rapidly scale up volume.

Industry Race: The "Three-Way Standoff" in the ITNS Track

Valencia is not the only player in this market. Boston Scientific’s move is essentially targeted at Medtronic andLaborieA Strategic Blockade:

• Medtronic: ItsPercepta™ ITNSThe system had previously received FDA Breakthrough Device designation. Medtronic has been striving to consolidate its dominance in the field of bladder management through ITNS.

• Laborie (Uroplasty): its launchedUrgent® PC(Percutaneous tibial nerve stimulation, non-implantable) is a pioneer in this field but requires patients to return to the clinic weekly for treatment. Valencia’s eCoin has achieved the leap “from non-implantable to implantable,” thoroughly resolving compliance issues.

# The overall comparison table is as follows:

# An Engineer's Perspective: Engineering Challenges and Breakthroughs in eCoin

For R&D engineers, the success of eCoin lies in solvingBalance Between Power and Volume：

• Leadless Encapsulation: In the highly mobile ankle region, leads are highly susceptible to fatigue and fracture. eCoin integrates the battery, chip, and electrodes into a single nitinol or ceramic housing, eliminating fragile leads.

• Antennas and Communications: Implantation in the ankle, where bony structures are prominent, poses significant challenges to radiofrequency signal transmission. Valencia Technologies has optimized the near-field communication (NFC) efficiency between the external programmer and the implant, ensuring that physicians can easily adjust parameters in the office setting.

# Conclusion

Boston Scientific’s Acquisition of Valencia Technologies Once Again Confirms a Core Strategy of Medical Device Giants:In mature sectors (such as urology), expand the boundaries of indications by acquiring disruptive technologies characterized by “outpatient-based, minimally invasive, and simplified” features.

As the transaction is expected to be completed in the first half of 2026, the ITNS sector will transition from a phase of “startup exploration” to one of “giant rivalry.” For domestic R&D enterprises, eCoin’s path—Identifying a Target for Long-Acting, Automated Therapy That Can Be Performed in an Office Setting Without Hospitalization—Potentially a key reference point for the next wave of global expansion or innovation in the field of neuromodulation.